Association of serum antibodies against p53 protein with poor survival in patients with Zollinger-Ellison syndrome.

[1]  M. Mignon,et al.  Processing‐independent assay of serum gastrin for diagnosis of liver metastases in the Zollinger‐Ellison syndrome , 1997, International Journal of Cancer.

[2]  J. Kouyoumdjian,et al.  Detection and monitoring of serum p53 antibodies in patients with colorectal cancer. , 1997, Gut.

[3]  E. Diamandis,et al.  Humoral immune response against p53 protein in patients with colorectal carcinoma , 1997, International journal of cancer.

[4]  S. Kudo,et al.  Detection of circulating anti-p53 antibodies in patients with colorectal carcinoma and the antibody's relation to clinical factors , 1996, Diseases of the colon and rectum.

[5]  K. Pavelić,et al.  Concomitant point mutation of tumor suppressor gene p53 and oncogene c-N-ras in malignant neuroendocrine pancreatic tumor. , 1996, Anticancer Research.

[6]  J. Belghiti,et al.  p53 protein expression and DNA ploidy in cystic tumors of the pancreas. , 1996, Pancreas.

[7]  J. Bourhis,et al.  Analysis of p53 serum antibodies in patients with head and neck squamous cell carcinoma. , 1996, Journal of the National Cancer Institute.

[8]  C. Bartz,et al.  p53 tumour suppressor gene expression in pancreatic neuroendocrine tumour cells. , 1996, Gut.

[9]  S. H. van der Burg,et al.  Antibodies against p53 are associated with poor prognosis of colorectal cancer. , 1995, British Journal of Cancer.

[10]  T. Soussi,et al.  p53 antibodies in the sera of lung cancer patients: Comparison with p53 mutation in the tumour tissue , 1995, International journal of cancer.

[11]  D. Metz,et al.  Determinants of metastatic rate and survival in patients with Zollinger-Ellison syndrome: a prospective long-term study. , 1995, Gastroenterology.

[12]  J. Sloan,et al.  Overexpression of the tumour suppressor gene p53 is not implicated in neuroendocrine tumour carcinogenesis , 1995, The Journal of pathology.

[13]  J. Bonneterre,et al.  Prognostic significance of circulating P53 antibodies in patients undergoing surgery for locoregional breast cancer , 1995, The Lancet.

[14]  P. Laurent-Puig,et al.  Antibodies against p53 protein in serum of patients with benign or malignant pancreatic and biliary diseases. , 1995, Gut.

[15]  B. Iacopetta,et al.  Comparison of p53 gene mutation and protein overexpression in colorectal carcinomas. , 1994, British Journal of Cancer.

[16]  G. Cadiot,et al.  Clinical Features and Advances in Biological Diagnostic Criteria for Zollinger-Ellison Syndrome , 1994 .

[17]  W. Nealon,et al.  Gastrinomas Demonstrate Amplification of the HER‐2/neu Proto‐oncogene , 1994, Annals of surgery.

[18]  M. Satoh,et al.  Initiation of autoimmunity to the p53 tumor suppressor protein by complexes of p53 and SV40 large T antigen , 1994, The Journal of experimental medicine.

[19]  B. Kerem,et al.  Correlation between genotype and phenotype in patients with cystic fibrosis. , 1994, The New England journal of medicine.

[20]  N. Pellegata,et al.  K-ras and p53 gene mutations in pancreatic cancer: ductal and nonductal tumors progress through different genetic lesions. , 1994, Cancer research.

[21]  J. Berzofsky,et al.  Evidence for selection against human lung cancers bearing p53 missense mutations which occur within the HLA A*0201 peptide consensus motif. , 1994, Cancer research.

[22]  P. Laurent-Puig,et al.  Analysis of p53 antibodies in patients with various cancers define B-cell epitopes of human p53: distribution on primary structure and exposure on protein surface. , 1993, Cancer research.

[23]  M. Hollstein,et al.  Clinical implications of the p53 tumor-suppressor gene. , 1993, The New England journal of medicine.

[24]  C. S. Lee,et al.  Immunohistochemical demonstration of the p53 tumour suppressor gene product in cancer of the pancreas and chronic pancreatitis , 1993, Journal of gastroenterology and hepatology.

[25]  D. Metz,et al.  Flow cytometry and Zollinger-Ellison syndrome: relationship to clinical course. , 1993, Gastroenterology.

[26]  H. Zentgraf,et al.  The humoral immune response to p53 in patients with hepatocellular carcinoma is specific for malignancy and independent of the α‐fetoprotein status , 1993, Hepatology.

[27]  H P Koeffler,et al.  P53 mutations in human cancer. , 1993, Leukemia.

[28]  G. Thomas,et al.  Efficient screening of p53 mutations by denaturing gradient gel electrophoresis in colorectal tumors. , 1993, Oncogene.

[29]  G. Lauer,et al.  p53 and K-RAS alterations in pancreatic epithelial cell lesions. , 1993, Oncogene.

[30]  T. Sano,et al.  Role of p53 mutations in endocrine tumorigenesis: mutation detection by polymerase chain reaction-single strand conformation polymorphism. , 1992, Cancer research.

[31]  D. Lane,et al.  p53, guardian of the genome , 1992, Nature.

[32]  P. Shaw,et al.  Induction of apoptosis by wild-type p53 in a human colon tumor-derived cell line. , 1992, Proceedings of the National Academy of Sciences of the United States of America.

[33]  J. Marks,et al.  Immune response to p53 is dependent upon p53/HSP70 complexes in breast cancers. , 1992, Proceedings of the National Academy of Sciences of the United States of America.

[34]  B. Vogelstein,et al.  p53 mutations in human cancers. , 1991, Science.

[35]  B. Vogelstein,et al.  Suppression of human colorectal carcinoma cell growth by wild-type p53. , 1990, Science.

[36]  L. Bardram,et al.  Progastrin in serum from Zollinger-Ellison patients. An indicator of malignancy? , 1990, Gastroenterology.

[37]  A. Levine,et al.  The p53 proto-oncogene can act as a suppressor of transformation , 1989, Cell.

[38]  L. Cheung,et al.  Outcome of Lymph Node Involvement in Patients with the Zollinger‐Ellison Syndrome , 1988, Annals of surgery.

[39]  A. Levine,et al.  Activating mutations for transformation by p53 produce a gene product that forms an hsc70-p53 complex with an altered half-life , 1988, Molecular and cellular biology.

[40]  M. Bibbo,et al.  Nuclear DNA analysis of insulinomas and gastrinomas. , 1987, Surgery.

[41]  K. Chandrasekaran,et al.  Presence of circulating antibodies against cellular protein p53 in a notable proportion of children with B‐cell lymphoma , 1987, International journal of cancer.

[42]  R. Jensen,et al.  Cushing's syndrome in patients with the Zollinger-Ellison syndrome. , 1986, The New England journal of medicine.

[43]  D. O'Connor,et al.  Secretion of chromogranin A by peptide-producing endocrine neoplasms. , 1986, The New England journal of medicine.

[44]  M. Isobe,et al.  Localization of gene for human p53 tumour antigen to band 17p13 , 1986, Nature.

[45]  D. Pim,et al.  Detection of antibodies against the cellular protein p53 in sera from patients with breast cancer , 1982, International journal of cancer.

[46]  L. Wide,et al.  hCG and hCG subunits as tumour markers in patients with endocrine pancreatic tumours and carcinoids. , 1981, Acta endocrinologica.

[47]  V. Go.  The Pancreas : biology, pathobiology, and disease , 1993 .

[48]  H. Höfler,et al.  Identification of p53 gene mutations in gastrointestinal and pancreatic carcinoids by nonradioisotopic SSCA , 1993, Virchows Archiv. B, Cell pathology including molecular pathology.

[49]  E. Wilander,et al.  Nuclear DNA distribution in neuroendocrine gastroenteropancreatic tumors before and during treatment. , 1989, Acta oncologica.